| Identification | Back Directory | [Name]
Benzamide, 5-chloro-N-(3-chloro-4-nitrophenyl)-2-hydroxy- | [CAS]
56961-10-5 | [Synonyms]
SARS-CoV-2-IN-13
Benzamide, 5-chloro-N-(3-chloro-4-nitrophenyl)-2-hydroxy- | [Molecular Formula]
C13H8Cl2N2O4 | [MOL File]
56961-10-5.mol | [Molecular Weight]
327.12 |
| Chemical Properties | Back Directory | [Melting point ]
241 °C | [Boiling point ]
436.5±45.0 °C(Predicted) | [density ]
1.615±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 125 mg/mL (382.12 mM) | [form ]
Solid | [pka]
7.48±0.43(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1]. | [References]
[1] Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295. DOI:10.1016/j.ejmech.2022.114295 |
|
|